742 related articles for article (PubMed ID: 22690748)
1. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Richter JM; Kushkuley S; Barrett JA; Oster G
Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
[TBL] [Abstract][Full Text] [Related]
2. Ulcerative proctitis: a review of pharmacotherapy and management.
Lakatos PL; Lakatos L
Expert Opin Pharmacother; 2008 Apr; 9(5):741-9. PubMed ID: 18345952
[TBL] [Abstract][Full Text] [Related]
3. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
4. Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications.
Richter JM; Arshi NK; Oster G
Can J Gastroenterol Hepatol; 2016; 2016():6928710. PubMed ID: 27446860
[TBL] [Abstract][Full Text] [Related]
5. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
6. Topical therapy is underused in patients with ulcerative colitis.
Seibold F; Fournier N; Beglinger C; Mottet C; Pittet V; Rogler G;
J Crohns Colitis; 2014 Jan; 8(1):56-63. PubMed ID: 23566922
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
Watanabe M; Nishino H; Sameshima Y; Ota A; Nakamura S; Hibi T
Aliment Pharmacol Ther; 2013 Aug; 38(3):264-73. PubMed ID: 23734840
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
Cohen RD; Woseth DM; Thisted RA; Hanauer SB
Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
[TBL] [Abstract][Full Text] [Related]
10. Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository.
Kato S; Ishibashi A; Kani K; Yakabi K
Digestion; 2018; 97(1):59-63. PubMed ID: 29393142
[TBL] [Abstract][Full Text] [Related]
11. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
[TBL] [Abstract][Full Text] [Related]
12. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
Yamamoto T; Shimoyama T; Matsumoto K
Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
[TBL] [Abstract][Full Text] [Related]
13. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
[TBL] [Abstract][Full Text] [Related]
14. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
[TBL] [Abstract][Full Text] [Related]
15. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
Jo Y; Matsumoto T; Iida M
Nihon Rinsho; 2005 May; 63(5):820-4. PubMed ID: 15881176
[TBL] [Abstract][Full Text] [Related]
16. A combination of rectal beclomethasone diproprionate and mesalazine in ulcerative proctitis.
Guslandi M; Giollo P; Testoni PA
Scand J Gastroenterol; 2008; 43(5):639-40. PubMed ID: 18415762
[No Abstract] [Full Text] [Related]
17. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
Kruis W; Neshta V; Pesegova M; Alekseeva O; Andreev P; Datsenko O; Levchenko O; Abdulkhakov S; Lozynskyy Y; Mostovoy Y; Soloviev K; Dorofeyev AE; Vieth M; Stiess M; Greinwald R; Mohrbacher R; Siegmund B
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):98-106.e4. PubMed ID: 29702300
[TBL] [Abstract][Full Text] [Related]
18. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.
Regueiro M; Loftus EV; Steinhart AH; Cohen RD
Inflamm Bowel Dis; 2006 Oct; 12(10):979-94. PubMed ID: 17012969
[TBL] [Abstract][Full Text] [Related]
19. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
[TBL] [Abstract][Full Text] [Related]
20. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group.
d'Albasio G; Paoluzi P; Campieri M; Bianchi Porro G; Pera A; Prantera C; Sturniolo GC; Miglioli M
Am J Gastroenterol; 1998 May; 93(5):799-803. PubMed ID: 9625131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
